Prevalence of dementia among people experiencing homelessness in Ontario, Canada: a population-based comparative analysis
Booth R, Dasgupta M, Forchuk C, Shariff S. The Lancet Public Health. 2024; 9(4):e240-e249. Epub 2024 Mar 27.
Background — Preclinical and epidemiological data suggest that phosphoglycerate kinase 1 activators could have neuroprotective properties and prevent PD.
Objectives — The objective of this study was to compare the association between increased use of phosphoglycerate kinase 1 activators and increased use of tamsulosin with PD incidence.
Methods — Our retrospective cohort study included men older than age 66 years newly exposed to phosphoglycerate kinase 1 activators or tamsulosin and compared their PD incidence, using healthcare administrative data of Ontario, Canada.
Results — Among 265,745 men, each additional year of cumulative use of phosphoglycerate kinase 1 activators or tamsulosin was associated with 6% and 8% reduction, respectively, in the hazard of PD incidence. These hazards were not significantly different (P = 0.2094). A secondary analysis with the observation window starting after 6 months and 1 and 2 years showed similar results.
Conclusions — Increasing exposure to phosphoglycerate kinase 1 activators and tamsulosin were both associated with small reductions in PD incidence. These results support further investigation of phosphoglycerate kinase 1 activators and tamsulosin for possible PD disease-modifying properties. © 2021 International Parkinson and Movement Disorder Society.
Gros P, Wang X, Guan J, Lang AE, Austin PC, Welk B, Visanji NP, Marras C. Mov Disord. 2021; 36(10):2419-25. Epub 2021 Jul 9.
The ICES website uses cookies. If that’s okay with you, keep on browsing, or learn more about our Privacy Policy.